Overview

Latest Financial Results

Stock Information

Symbol

NASDAQ: CRBP

Price

Loading...

Change

Loading...

MKT Cap

Loading...

Volume

Loading...

Company Overview

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. The Company's lead product candidate, Resunab, is a first-in-class, synthetic oral endocannabinoid-mimetic drug that acts to resolve chronic inflammation, bacterial infections and fibrotic processes through an endogenous pathway. Resunab is currently being evaluated in four Phase 2 clinical trials for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis ("scleroderma"), dermatomyositis and systemic lupus erythematosus, four diseases in which inflammation contributes to disease progression.

Investor Presentation

Download Presentation